have successfully employed an algorithm to identify potential mutations which increase disease risk in the noncoding regions our DNA, which make up the vast majority of the human genome.

Detection of tumour-derived DNA fragments in a patient's bodily fluids (circulating tumour DNA [ctDNA]) has been anticipated to revolutionise oncological care for over a decade. Because of its tumour ...